JP2024539891A5 - - Google Patents
Info
- Publication number
- JP2024539891A5 JP2024539891A5 JP2024523533A JP2024523533A JP2024539891A5 JP 2024539891 A5 JP2024539891 A5 JP 2024539891A5 JP 2024523533 A JP2024523533 A JP 2024523533A JP 2024523533 A JP2024523533 A JP 2024523533A JP 2024539891 A5 JP2024539891 A5 JP 2024539891A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- solid dispersion
- compound
- solvate
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163271977P | 2021-10-26 | 2021-10-26 | |
| US63/271,977 | 2021-10-26 | ||
| PCT/US2022/047769 WO2023076305A1 (en) | 2021-10-26 | 2022-10-25 | Compositions comprising an erk inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539891A JP2024539891A (ja) | 2024-10-31 |
| JP2024539891A5 true JP2024539891A5 (https=) | 2025-10-27 |
Family
ID=84367494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523533A Pending JP2024539891A (ja) | 2021-10-26 | 2022-10-25 | Ｅｒｋ阻害剤を含んでなる組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240415835A1 (https=) |
| EP (1) | EP4422604A1 (https=) |
| JP (1) | JP2024539891A (https=) |
| KR (1) | KR20240089586A (https=) |
| CN (1) | CN118119381A (https=) |
| AU (1) | AU2022376165A1 (https=) |
| CA (1) | CA3235680A1 (https=) |
| WO (1) | WO2023076305A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068392T2 (hu) * | 2015-10-21 | 2024-12-28 | Otsuka Pharma Co Ltd | Benzolaktám vegyületek mint fehérje kináz gátlók |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068392T2 (hu) | 2015-10-21 | 2024-12-28 | Otsuka Pharma Co Ltd | Benzolaktám vegyületek mint fehérje kináz gátlók |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
-
2022
- 2022-10-25 US US18/702,752 patent/US20240415835A1/en active Pending
- 2022-10-25 AU AU2022376165A patent/AU2022376165A1/en active Pending
- 2022-10-25 KR KR1020247015609A patent/KR20240089586A/ko active Pending
- 2022-10-25 EP EP22814554.6A patent/EP4422604A1/en active Pending
- 2022-10-25 CA CA3235680A patent/CA3235680A1/en active Pending
- 2022-10-25 CN CN202280070421.4A patent/CN118119381A/zh active Pending
- 2022-10-25 WO PCT/US2022/047769 patent/WO2023076305A1/en not_active Ceased
- 2022-10-25 JP JP2024523533A patent/JP2024539891A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024539891A5 (https=) | ||
| EP1778201B1 (en) | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof | |
| WO2022100641A1 (zh) | 包含egfr抑制剂的药物组合物及其制备方法 | |
| JP7051638B2 (ja) | エスシタロプラム医薬組成物 | |
| EP4159203B1 (en) | Oral sustained-release composition for insoluble drug, and preparation method thereof | |
| WO2013054872A1 (ja) | ７－［４－（４－ベンゾ［ｂ］チオフェン－４－イル－ピペラジン－１－イル）ブトキシ］－１Ｈ－キノリン－２－オン又はその塩を含む錠剤 | |
| JP2011503017A (ja) | ヒドロモルホン含有徐放性錠剤 | |
| JP2020533283A5 (https=) | ||
| WO2021223480A1 (zh) | 一种替格瑞洛控释片及其制备方法 | |
| JP6293315B2 (ja) | アリサルタン・イソプロキシル固体分散体及び該固体分散体を含有する医薬組成物 | |
| CN112022812A (zh) | 一种包含杂环类化合物的组合物、其制备方法和应用 | |
| JP2006501274A (ja) | オキシカルバゼピンおよびその誘導体の改良放出製剤 | |
| AU2009243734B2 (en) | Granulate comprising escitalopram oxalate | |
| CN119300811A (zh) | 高剂量因多昔芬制剂和使用方法 | |
| CN114096530B (zh) | 一种复合物的药物组合物及其制备方法 | |
| MX2013010598A (es) | Composiciones farmaceuticas de liberacion controlada de inhibidor de recaptacion de serotonina selectivo. | |
| KR101128891B1 (ko) | 로라타딘 및 슈도에페드린을 함유하는 제어 방출 다층정 | |
| CN104800184A (zh) | 琥珀酸呋罗曲坦缓释剂片 | |
| CN114053237A (zh) | 一种控释片剂及其制备方法 | |
| CN101756981B (zh) | 一种布洛氯雷伪麻缓释制剂及其制备方法 | |
| TWI745598B (zh) | 非布司他控釋組合物及其製備方法 | |
| JP6787928B2 (ja) | リバスチグミン含有徐放出医薬組成物 | |
| CN118662470A (zh) | 一种非奈利酮胶囊剂及其制备方法 | |
| JP2024500545A5 (https=) | ||
| CN115844856B (zh) | 一种双环醇固体制剂及其制备方法 |